Taltz for Laryngostenosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether Taltz can help people with idiopathic subglottic stenosis, a condition where the airway below the vocal cords narrows without a known cause. Researchers aim to determine if Taltz can reduce scar tissue growth in the airway, potentially helping patients avoid or undergo fewer surgeries. The trial seeks participants diagnosed with idiopathic subglottic stenosis who are willing to join the study. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking drugs that trigger angioedema, like ACE inhibitors (e.g., Lisinopril) or NSAIDs.
Is there any evidence suggesting that Taltz is likely to be safe for humans?
Research has shown that Taltz, also known as ixekizumab, maintains a consistent safety record across various studies. In trials involving patients with conditions like psoriasis and psoriatic arthritis, the most common side effects were mild, including injection site reactions, colds, nausea, and fungal infections. Serious side effects occurred rarely, and overall safety remained stable even with long-term use.
This suggests that Taltz is generally well-tolerated. However, because this new study focuses on laryngostenosis (a throat condition), monitoring for any potential side effects specific to this condition is important.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for laryngostenosis, which typically involve surgical procedures or steroid injections to manage the condition, Taltz offers a unique approach by targeting the underlying inflammation. Taltz is an IL-17A inhibitor, a type of medication that specifically blocks a protein involved in inflammatory responses, which might help reduce the narrowing of the larynx without invasive methods. Researchers are excited about Taltz because it has the potential to provide a non-surgical option that directly addresses inflammation, possibly leading to better outcomes with fewer side effects.
What evidence suggests that Taltz might be an effective treatment for laryngostenosis?
Studies have shown that Taltz (also known as ixekizumab) effectively treats various conditions by targeting IL-17A, a protein that causes inflammation. For instance, 76% of patients with psoriatic arthritis experienced significant improvement after one year. In psoriasis, Taltz led to complete skin clearance in many cases, with 83% of those with scalp psoriasis achieving this outcome. Although these studies focus on conditions other than laryngostenosis, they demonstrate Taltz’s ability to reduce inflammation, which is crucial in preventing scarring and tissue thickening. This suggests it might help reduce scar tissue growth in laryngostenosis.16789
Who Is on the Research Team?
Nwanmegha Young, MD
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for individuals with idiopathic subglottic stenosis, a narrowing of the airway below the vocal cords. Participants must consent to study procedures and be available throughout the study. It excludes those with tuberculosis history, pregnant or lactating women, people with inflammatory bowel disease, or allergies to Taltz.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Taltz to inhibit IL-17A activation, aiming to decrease scar fibroblast proliferation and reduce the need for surgeries
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Taltz
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Lilly PharmaceuticalCompany
Collaborator